Glomerular filtration rate estimated by cockcroft-gault formula better predicts anti-xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin

Journal of Nutrition, Health and Aging

Volumn 16, Issue 7, 2012, Pages 647-652

  Dufour, B ^a   Toussaint Hacquard, M ^a   Kearney Schwartz, A ^a,b   Manckoundia, M D P ^c   Laurain, M C ^a   Joly, L ^a   Deibener, J ^a   Wahl, D ^a,b   Lecompte, T ^a,b   Benetos, A ^a,b   Perret Guillaume, C ^a,b,d  

^a CHU NANCY BRABOIS   (France)

^b INSERM   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Glomerular filtration rate estimation; Molecular weight heparin; Older

Indexed keywords

ENOXAPARIN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; COCKCROFT GAULT FORMULA; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; FEMALE; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MODIFICATION OF THE DIET IN RENAL DISEASE EQUATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; UNIVARIATE ANALYSIS; VENOUS THROMBOEMBOLISM;

EID: 85027934774     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0072-6     Document Type: Article

References (30)

1. Oger, E. (2000) Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83: 657-660.
2. Anderson, F. A., Jr., Wheeler, H. B., Goldberg, R. J., Hosmer, D. W., Patwardhan, N. A., Jovanovic, B., Forcier, A. & Dalen, J. E. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151: 933-938.
3. Samama, M. M., Cohen, A. T., Darmon, J. Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C. G. et al. (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793-800.
4. Leizorovicz, A., Cohen, A. T., Turpie, A. G., Olsson, C. G., Vaitkus, P. T. & Goldhaber, S. Z. (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110: 874-879.
5. Cohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G., Egberts, J. F. & Lensing, A. W. (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. Bmj 332: 325-329.
6. Hirsh, J. & Raschke, R. (2004) Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S-203S.
7. Leizorovicz, A., Siguret, V., Mottier, D., Leizorovicz, A., Siguret, V., Mottier, D., Clonier, F., Janas, M., Stinson, J. et al. (2011) Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep(R) in Renal Insufficiency Study (IRIS). Thromb Res 128: 27-34.
8. Duneton, P. (2000) Héparines de Bas Poids Moléculaire et Risque Hémorragique. Lettres aux prescripteurs., Affsaps ed. Paris.
9. Mismetti, P., Laporte-Simitsidis, S., Navarro, C., Sie, P., d'Azemar, P., Necciari, J., Duret, J. P., Gaud, C., Decousus, H. & Boneu, B. (1998) Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 79: 1162-1165.
10. Lim, W., Dentali, F., Eikelboom, J. W. & Crowther, M. A. (2006) Meta-analysis: Lowmolecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144: 673-684.
11. Bounameaux, H. & Reber, G. (2010) New oral antithrombotics: A need for laboratory monitoring. Against. J Thromb Haemost 8: 627-630.
12. (2006) French Drug Agency. Low molecular weight heparins and haemorrhagic risk (letter).
13. Lamb, E. J., Webb, M. C. & O'Riordan, S. E. (2007) Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people. Age Ageing 36: 689-692.
14. Pequignot, R., Belmin, J., Chauvelier, S., Gaubert, J. Y., Konrat, C., Duron, E. & Hanon, O. (2009) Renal Function in Older Hospital Patients Is More Accurately Estimated Using the Cockcroft-Gault Formula Than the Modification Diet in Renal Disease Formula. J Am Geriatr Soc 57:1638-43.
15. Cockcroft, D. W. & Gault, M. H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
16. Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N. & Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470.
17. Levey, A. S., Eckardt, K. U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., De Zeeuw, D., Hostetter, T. H., Lameire, N. & Eknoyan, G. (2005) Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100.
18. Laposata, M., Green, D., Van Cott, E. M., Barrowcliffe, T. W., Goodnight, S. H. & Sosolik, R. C. (1998) College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of lowmolecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122: 799-807.
19. Mahe, I., Gouin-Thibault, I., Drouet, L., Simoneau, G., Di Castillo, H., Siguret, V., Bergmann, J. F. & Pautas, E. (2007) Elderly medical patients treated with prophylactic dosages of enoxaparin: Influence of renal function on anti-Xa activity level. Drugs Aging 24: 63-71.
20. Gouin-Thibault, I., Pautas, E., Mahe, I., Descarpentries, C., Nivet-Antoine, V., Golmard, J. L. & Siguret, V. (2007) Is Modification of Diet in Renal Disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin? J Gerontol A Biol Sci Med Sci 62: 1300-1305.
21. Berges, A., Laporte, S., Epinat, M., Zufferey, P., Alamartine, E., Tranchand, B., Decousus, H. & Mismetti, P. (2007) Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 64: 428-438.
22. Desjardins, L., Bara, L., Boutitie, F., Samama, M. M., Cohen, A. T., Combe, S., Janbon, C., Leizorovicz, A., Olsson, C. G. & Turpie, A. G. (2004) Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 128: 519-526.
23. Levin, A., Ben-Artzi, M., Beckerman, P., Haber, G., Varon, D., Ben-Yehuda, A. & Muszkat, M. (2009) Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : A prospective, open-label, observational study. Drugs Aging 26: 77-85.
24. Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R. & Colwell, C. W. (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S-453S.
25. Patel, J. P., Roberts, L. N. & Arya, R. (2011) Anticoagulating obese patients in the modern era. Br J Haematol. Aug 16, [Epub ahead of print]
26. Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M. & Weitz, J. I. (2008) Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 141S-159S.
27. Bara, L., Planes, A. & Samama, M. M. (1999) Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 104: 230-240.
28. Montalescot, G., Collet, J. P., Tanguy, M. L., Ankri, A., Payot, L., Dumaine, R., Choussat, R., Beygui, F., Gallois, V. & Thomas, D. (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110: 392-398.
29. Mismetti, P. & Laporte, S. (2010) New oral antithrombotics: A need for laboratory monitoring. For. J Thromb Haemost 8: 621-626.
30. Pedone, C., Corsonello, A. & Incalzi, R. A. (2006) Estimating renal function in older people: A comparison of three formulas. Age Ageing 35: 121-126.